Literature DB >> 23801770

Global small bowel motility: assessment with dynamic MR imaging.

Alex Menys1, Stuart A Taylor, Anton Emmanuel, Asia Ahmed, Andrew A Plumb, Freddy Odille, Ahsan Alam, Steve Halligan, David Atkinson.   

Abstract

PURPOSE: To assess the repeatability in human volunteers of software-quantified small bowel motility captured with magnetic resonance (MR) imaging and to test the ability to detect changes in motility induced by pharmacologic agents.
MATERIALS AND METHODS: The study was approved by the Royal Free Research Ethics Committee, and all subjects gave full written informed consent. Twenty-one healthy volunteers (14 men, seven women; mean age, 28 years) underwent cine MR imaging with a three-dimensional balanced turbo field-echo sequence to capture small bowel motility. Volume blocks (15 cm thick) were acquired every second during a 20-second breath hold. A randomized, blinded, placebo-controlled crossover study of either 0.5 mg neostigmine or saline (n = 11) or 20 mg intravenous butylscopolamine or saline (n = 10) was performed with motility MR imaging at baseline and repeated at a mean of 4 weeks (range, 2-7 weeks). Two readers independently drew regions of interest around the small bowel, and motility was quantified by using a registration algorithm that provided a global motility metric in arbitrary units. Repeatability of the motility measurements at baseline was assessed by using Bland-Altman and within-subject coefficient of variation measures. Changes in mean motility measurements after drug administration were compared with those after placebo administration by using paired t testing.
RESULTS: The repeatability between baseline measurements of motility was high; the Bland-Altman mean difference was -0.0025 (range, 0.28-0.4), the 95% limit of agreement was ±0.044 arbitrary units (au), and the within-subject coefficient of variation was 4.9%. Measured motility with neostigmine (mean, 0.39 au) was significantly higher than that with placebo (mean, 0.34 au; P < .001), whereas that with butylscopolamine (mean, 0.13 au) was significantly lower than that with placebo (mean, 0.30 au; P < .001).
CONCLUSION: Quantification of small bowel motility with use of MR imaging in healthy volunteers is repeatable and sensitive to changes induced by means of pharmacologic manipulation. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13130151/-/DC1. RSNA, 2013

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801770     DOI: 10.1148/radiology.13130151

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  Vagus nerve stimulation promotes gastric emptying by increasing pyloric opening measured with magnetic resonance imaging.

Authors:  K-H Lu; J Cao; S Oleson; M P Ward; R J Phillips; T L Powley; Z Liu
Journal:  Neurogastroenterol Motil       Date:  2018-05-24       Impact factor: 3.598

2.  Diffusion-weighted MR enterography for evaluating Crohn's disease: Effect of anti-peristaltic agent on the diagnosis of bowel inflammation.

Authors:  So Hyun Park; Jimi Huh; Seong Ho Park; Seung Soo Lee; Ah Young Kim; Suk-Kyun Yang
Journal:  Eur Radiol       Date:  2016-10-05       Impact factor: 5.315

Review 3.  Will MRI of gastrointestinal function parallel the clinical success of cine cardiac MRI?

Authors:  Caroline Hoad; Christopher Clarke; Luca Marciani; Martin John Graves; Maura Corsetti
Journal:  Br J Radiol       Date:  2018-10-24       Impact factor: 3.039

4.  Update on Magnetic Resonance Imaging and Ultrasound Evaluation of Crohn's Disease.

Authors:  Parakkal Deepak; Amy B Kolbe; Jeff L Fidler; Joel G Fletcher; John M Knudsen; David H Bruining
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-04

5.  Cardiac-induced liver deformation as a measure of liver stiffness using dynamic imaging without magnetization tagging-preclinical proof-of-concept, clinical translation, reproducibility and feasibility in patients with cirrhosis.

Authors:  Manil D Chouhan; Heather E Fitzke; Alan Bainbridge; David Atkinson; Steve Halligan; Nathan Davies; Mark F Lythgoe; Rajeshwar P Mookerjee; Alex Menys; Stuart A Taylor
Journal:  Abdom Radiol (NY)       Date:  2021-06-20

Review 6.  Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' project.

Authors:  Bart Hens; Patrick D Sinko; Nicholas Job; Meagan Dean; Jozef Al-Gousous; Niloufar Salehi; Robert M Ziff; Yasuhiro Tsume; Marival Bermejo; Paulo Paixão; James G Brasseur; Alex Yu; Arjang Talattof; Gail Benninghoff; Peter Langguth; Hans Lennernäs; William L Hasler; Luca Marciani; Joseph Dickens; Kerby Shedden; Duxin Sun; Gregory E Amidon; Gordon L Amidon
Journal:  Int J Pharm       Date:  2018-06-23       Impact factor: 5.875

Review 7.  Real-Time Magnetic Resonance Imaging.

Authors:  Krishna S Nayak; Yongwan Lim; Adrienne E Campbell-Washburn; Jennifer Steeden
Journal:  J Magn Reson Imaging       Date:  2020-12-09       Impact factor: 4.813

8.  Indications and selection of MR enterography vs. MR enteroclysis with emphasis on patients who need small bowel MRI and general anaesthesia: results of a survey.

Authors:  Michael R Torkzad; Gabriele Masselli; Steve Halligan; Aytek Oto; Henning Neubauer; Stuart Taylor; Arun Gupta; Jens Brøndum Frøkjær; Ian C Lawrance; Christopher J Welman; Anne Negård; Olle Ekberg; Michael Patak; Thomas Lauenstein
Journal:  Insights Imaging       Date:  2015-04-09

9.  Fasted and fed small bowel motility patterns at cine-MRI in chronic intestinal pseudo-obstruction.

Authors:  Kyra L van Rijn; Albert J Bredenoord; André J P M Smout; Gerd Bouma; Jeroen A W Tielbeek; Karin Horsthuis; Jaap Stoker; Catharina S de Jonge
Journal:  Neurogastroenterol Motil       Date:  2020-12-27       Impact factor: 3.598

Review 10.  Magnetic resonance imaging biomarkers of gastrointestinal motor function and fluid distribution.

Authors:  Asseel Khalaf; Caroline L Hoad; Robin C Spiller; Penny A Gowland; Gordon W Moran; Luca Marciani
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.